- Closed ~$1.89 (+213.8% vs Friday's $0.60) after the FDA granted accelerated approval to Voceryq, the first plasmid DNA immunotherapy.
- Peaked ~$2.27 premarket, opened $1.99, dipped to $1.66, then reclaimed $2.00 by midday.
- Volume ~221.5M shares, ~33x average — the largest turnover in the biotech universe that day.
- Closed ~$11.41 (+31.2% vs $8.70) as Affle's $11.70/share all-cash buyout held the tape.
- Traded $11.37-$11.43 all session, about 2.6% below the deal price, on ~7.8M shares.
- A 40-day go-shop runs to December 11; closing is expected in early 2027.
- Closed ~$2.47 (-13.3% vs $2.85) on Q3 EPS of $0.06 vs $0.13 expected and revenue of $410M vs ~$466M.
- Gapped down to a $2.55 open and traded $2.38-$2.60 on ~39.4M shares.
- Q4 production guidance of 60,000-64,000 barrels a day sits below Q3 levels.
- Closed ~$104.77 (-4.1% vs $109.23) despite Q1 EPS of $0.72 vs $0.52 expected and raised fiscal 2027 guidance.
- Opened $112.26, hit a $113.50 high, then slid to a $103.09 low as the gap reversed all session.
- Volume ~8.5M shares, roughly 3x the 30-day average.
- Closed ~$137.83 (-4.0% vs Friday's ~$143.54) after Morgan Stanley cut the stock to Underweight and slashed its target 53% to $120.
- The bank cited weak trading trends and a soft revenue outlook after the $6.3B Binance hack.
- Ark bought $3.4M of shares into the weakness through ARKK, ARKW and ARKF.
Useful?